ReNeuron Group (AIM: RENE)

Currency in GBP

Last close As at 07/06/2023

GBP0.08

1.80 (30.77%)

Market capitalisation

GBP3m

UK-based ReNeuron Group operates as a contract research and development organisation (CDRO) and is focused on its stem cell-derived exosome drug delivery platform, CustomEx. Its established partners are progressing the preclinical development of exosome-based therapeutics utilising its CustomEx technology.

Drug delivery remains a major challenge in both central nervous system (CNS) and cell and gene drug development, and we view these as key markets for ReNeuron to target with its exosome drug delivery platform. Additionally, ReNeuron’s diversification in exosome-producing stem cell lines and ability to produce exosomes with enhanced natural tissue targeting affinity, particularly neural stem cell lines to target CNS indications, may offer market differentiation against single cell line competitors.

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Ian Ross

    Chairman

  • John Hawkins

    CFO

  • John Sinden

    Chief Scientific Officer

Balance Sheet

Forecast net cash (£m)

11

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (30.4) (42.9) (82.5)
Relative (27.1) (39.7) (82.2)
52 week high/low 34.0p/5.8p

Financials

ReNeuron Group is a UK biotech focused on the development of its stem cell-derived exosome drug delivery platform, CustomEx. The company operates as a CRDO and has established seven discovery stage collaborations with pharma, biotech and academic institutions, through which its proprietary CustomEx exosome platform is being investigated for application in targeted drug delivery. ReNeuron’s exosomes have shown encouraging preclinical proof-of-concept data to deliver complex therapeutic payloads with high tissue specificity.

Y/E Mar Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.4 N/A (11.1) (17.01) N/A N/A
2023A 0.5 N/A (6.7) (9.47) N/A N/A
2024E 0.9 N/A (7.1) (10.53) N/A N/A
2025E 12.3 N/A 3.9 5.72 1.0 0.9

Further insights

Healthcare

Stem cells

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free